Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03498313 · ClinicalTrials.gov registry record · Phase 4
Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
A Phase 4 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT03498313 is a Phase 4 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 60 participants.
The verdict
NCT03498313, a Phase 4 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This within-person, crossover, 3-condition, placebo-controlled study compares the impact of three perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The three conditions are (1) perimenstrual withdrawal from estradiol only (during progesterone stabilization), (2) perimenstrual withdrawal from progesterone only (during estradiol stabilization), and (3) perimenstrual withdrawal from both estradiol and progesterone during placebo.
Interventions
- DRUG Placebos
- DRUG Transdermal Estradiol + Placebo
- DRUG Oral Micronized Progesterone + Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2021-05-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03498313
The ClinicalTrials.gov registry entry for NCT03498313 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT03498313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03498313 about?
NCT03498313 is a clinical study titled "Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality". This within-person, crossover, 3-condition, placebo-controlled study compares the impact of three perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The three conditions are (1) perimenstrual withdrawal from ...
What is the current status of trial NCT03498313?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2018-07-27. Estimated completion is 2021-05-09.
What interventions are being tested in trial NCT03498313?
The interventions under investigation include: Placebos (DRUG), Transdermal Estradiol + Placebo (DRUG), Oral Micronized Progesterone + Placebo (DRUG).
Who is sponsoring clinical trial NCT03498313?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.